Rights and permissions
About this article
Cite this article
Infliximab may be cost effective in severe, treatment-resistant RA. Pharmacoecon. Outcomes News 480, 9 (2005). https://doi.org/10.2165/00151234-200504800-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504800-00025